

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
06171/105005	09/371,747	August 10, 1999
APPLICANT		GROUP Art Unit
Gosselin et al.		-1614 -- 1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK	*					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
AL	2 WO 99/45935	09/16/99	World (PCT)	Lipitek International, Inc.	
AM	WO 96/13512 A2 / A3	05/09/96	WORLD (PCT)	Genencor INT; Lipiteck INC.	
AN	WO 92/08727	05/29/92	World (PCT)	Consiglio Nazionale Richerche	
AO	EP 0 352 248	01/24/90	Europe (EPO)	Medivir AB	
AP	CA 2,206,878	03/27/97	Canada	Lipitek International Inc.	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	✓	(Erroneous citation - see PTO-892 for correct cite. Robins, Morris J., "Selective Deoxygenation and Modification at C2' of Nucleosides" Nucleic Acids Chem., 98(13), (1983-03-28), XP002134809,
CB	✓	Zhu, Yong-Lian et al, "Anti -Hepatitis B Virus Activity and Metabolism of 2',3'-Dideoxy-2',3'-Didehydro-beta-L(-)-5-Fluorocytidine", Antimicrob Agents Chemother. (1998) 42(7), 1805-1810, XP 002134808 (7/98)
CC	✓	Lin T-S et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents, Tetrahedron 51(4), 1055-1068, (1995-01-23)

EXAMINER	L. E. Crane	DATE CONSIDERED
		12/21/00


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Month of publication data is unavailable for this reference.

COPY FOR File Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	1	of	4	Attorney Docket Number	NOV 1000 06171.105005



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
gke	AA	5,149,794		Yatvin et al	09-22-1992
gke	AB	5,194,654		Hostetler et al.	03-16-1993
gke	AC	5,223,263		Hostetler et al.	06-29-1993
gke	AD	5,256,641		Yatvin et al	10-01-1993
gke	AE	5,411,947		Hostetler et al.	05-02-1995
gke	AF	5,463,092		Hostetler et al.	10-31-1995
gke	AG	5,539,116		Liotta	07-23-1996
gke	AH	5,543,389		Yatvin et al	08-06-1996
gke	AI	5,543,390		Yatvin et al	08-06-1996
gke	AJ	5,543,391		Yatvin et al	08-06-1996
gke	AK	5,554,728		Basava et al.	09-10-1996
gke	AL	5,565,438		Chu	10-15-1996
gke	AM	5,567,688		Chu	10-22-1996
gke	AN	5,587,362		Chu	12-24-1996
**	AO	09/330,133		Sehineazi et al.	
gke	AP	5,190,926		Chu	03-02-1993
gke	AQ	4,916,122		Chu	04-10-1990

** Allowed file unavailable at this time.

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office		Number				
gke	AR	WO		89/02733 ✓	University of California	04-06-1989		✓
gke	AS	WO		90/00555 ✓	Vical, Inc.	01-25-1990		
gke	AT	WO		91/16920 ✓	Vical, Inc.	11-14-1991		
gke	AU	WO		91/18914 ✓	Vical, Inc.	12-12-1991		
gke	AV	WO		91/19721 ✓	Glazier	12-26-1991		
gke	AW	WO		92/15308 ✓	Wellcome	09-17-1992		
gke	AX	WO		92/18517. ✓	Yale et al.	10-29-1992		

Examiner Signature	L. E. Crane <i>L. E. Crane</i>	Date Considered	12/21/00
--------------------	--------------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>Sheet 2 of 4</p>				<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>09/371,747</td> </tr> <tr> <td>Filing Date</td> <td>August 10, 1999</td> </tr> <tr> <td>First Named Inventor</td> <td>Gosselin et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>-1614- 1623</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>NOV 1000</td> </tr> </table> <p style="text-align: right;">O I P E NOV 7/00 MAY 18 2000 PATENT & TRADEMARK OFFICE</p>		Application Number	09/371,747	Filing Date	August 10, 1999	First Named Inventor	Gosselin et al.	Group Art Unit	-1614- 1623	Examiner Name		Attorney Docket Number	NOV 1000
Application Number	09/371,747																
Filing Date	August 10, 1999																
First Named Inventor	Gosselin et al.																
Group Art Unit	-1614- 1623																
Examiner Name																	
Attorney Docket Number	NOV 1000																


FOREIGN PATENT DOCUMENTS


***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

COPY FOR File Applicant

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/371,747
Sheet	3	of	4	Filing Date	August 10, 1999
				First Named Inventor	Gosselin et al.
				Group Art Unit	1614 - 1623
				Examiner Name	
				Attorney Docket Number	NOV 1000 06171.105005




OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
JK	CA	Chang, et al., Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2',3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication, Journal of Biological Chemistry, Volume 267(20), 13938-13942 (1992). (July, 1992).			
JK	CB	Davisson, et al., Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides, J. Org. Chem., 52(9), 1794-1801 (1987)			
JK	CC	Du J et al, Synthesis, "Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides," J of Med. Chem., (40)19, 2991-2993 (1997). (September 12, 1997).			
JK	CD	Furman, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" Antimicrobial Agents and Chemotherapy, 36(12) 2686-2692 (1992). (December, 1992).			
JK	CE	Hoard, et al., Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates, J. Am. Chem. Soc., 87(8), 1785-1788 (1965). (April-June, 1965).			
JK	CF	Antonin Holy "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," Collect. Czech. Chem. Commun. (1972), 37(12), 4072-87. (December, 1972).			
JK	CG	Hostetler, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch. 1992. Antimicrob Agents Chemother. 36:2025-2029 (September, 1992).			
JK	CH	Hostetler, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman. 1990. J. Biol Chem. 265:6112-7. (April 15, 1990).			
JK	CI	VERRI, Biochem. J. (1997), 328(1), 317-20. (November 15, 1997).			
JK	CJ	Gosselin, G.; Bergogne, M.-C.; Imbach, J.-L., "Synthesis and Antiviral Evaluation of -L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases", Journal of Heterocyclic Chemistry, 1993, 30 (Oct.-Nov.), 1229-1233			
JK	CK	Bloch, et al. (J. Med. Chem. (1967), 10(5), 908-12). (September, 1967).			
JK	CL	Kucera, L.S., N. Lyer, E. Leake, A. Raben, Modest E.J., D. L.W., and C. Piantadosi. 1990. AIDS Res Hum Retroviruses. 6:491-501; (Issue No. 4; Q April, 1990).			
		! Month of publication data is unavailable for this reference.			
Examiner Signature	L. E. Crane 			Date Considered	12/21/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/371,747
Sheet	4	of	4	Filing Date	August 10, 1999
				First Named Inventor	Gosselin et al.
				Group Art Unit	1614- 1623
				Examiner Name	
				Attorney Docket Number	NOV 1000 06171.105005



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
ME	DA1	R. Jones and N. Bischofberger, Mini Review: Nucleotide prodrugs, Antiviral Research, 27, 1-17 (1995).	
ME	DB1	Imai et al., J. Org. Chem., 34(6), 1547-1550 (June 1969).	
ME	DC1	Nakayama, C., and Saneyoshi, M., Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1- Xylofuranosyl-5-Alkyluracils and Related Nucleosides. Nucleosides, Nucleotides, 1, 139-146 (1982)	
ME	DD1	MAGA et al., Biochem. J. (1993), 294(2), 381-5. (September 1, 1993).	
ME	DE1	Robins, M.J., et al., Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxyribonucleosides. J. Am. Chem. Soc. 105, 4059-4065 (1983).	
ME	DF1	Korba and Milman, A cell culture assay for compounds which inhibit hepatitis B virus replication, Antiviral Res., 15:217 1991. (Issue No. 1, January, 1991).	
ME	DG1	SPADARI, J. Med. Chem. (1992), 35(22), 4214-20.	
ME	DH1	Morris S. Zedek et al. Pseudomonas testosteroni, Mol. Phys. (1967), 3(4), 386-95.	
ME	DI1	Robins, M. J.; Khwaja, T. A.; Robins, R. K. J. Org. Chem. 1970, 35, 636-639] (Issue No. 3; March, 1970).	
ME	DJ1	Saneyoshi, M., and Satoh, E., Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines. Chem. Pharm. Bull., 27, 2518-2521 (1979);	
ME	DK1	Tyrsted et al. (Biochim. Biophys. Acta (1968), 155(2), 619-22)	
ME	DL1	Verri et al. Mol. Pharmacol. (1997), 51(1), 132-138 (January, 1997).	
ME	DM1	Zhang, W., and Robins, M. J., Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol. Tetrahedron Lett., 33, 1177-1180 (1992). (February 25, 1992).	
ME	DN1	Norbeck, Tetrahedron Letters 30 (46), 6246 (1989)	

Examiner Signature	L. E. Crane 	Date Considered	12/21/00
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

COPY FOR File Applicant